Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Juliusson

Showing results (41-50 of 114) with videos related to

Pageof 12
Sort By:
Blood Reviews|September 1, 1987
Role of chromosomal abnormalities in chronic lymphocytic leukemiaG Gahrton, G Juliusson, K H Robèrt, et al.
Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section A, Pathology|March 1, 1986
Haematological remission of leukaemic polymorphic immunocytoma following splenectomy. Case report with longitudinal immunological and cytogenetic studiesG Juliusson, A Ost, P Biberfeld, et al.
British Journal of Haematology|July 1, 1985
Prognostic value of B-cell mitogen-induced and spontaneous thymidine uptake in vitro in chronic B-lymphocytic leukaemia cellsG Juliusson, K H Robèrt, B Nilsson, et al.
European Journal of Cancer Care|July 10, 2015
Frequent and long-term follow-up of health-related quality of life following allogeneic haematopoietic stem cell transplantationU Frödin, K Lotfi, V Fomichov, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|March 10, 1994
[Progress in the treatment of hairy cell leukemia. Subcutaneous administration of 2-chloro-deoxy-adenosine for 7 days]D Heldal, G E Tjønnfjord, S A Evensen, et al.
British Journal of Haematology|March 1, 1995
Low-dose cladribine for symptomatic hairy cell leukaemiaG Juliusson, R Lenkei, G Tjønnfjord, et al.
Bone Marrow Transplantation|January 18, 2006
Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survivalG Juliusson, N Theorin, K Karlsson, et al.
Therapeutic Drug Monitoring|August 1, 1994
Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extractionF Albertioni, B Pettersson, V Reichelová, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL)F Albertioni, S Lindemalm, S Eriksson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosineV Reichelová, G Juliusson, T Spasokoukotskaja, et al.
Pageof 12

Showing results (41-50 of 114) with videos related to

Sort By:
Pageof 12
Blood Reviews|September 1, 1987
Role of chromosomal abnormalities in chronic lymphocytic leukemiaG Gahrton, G Juliusson, K H Robèrt, et al.
Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section A, Pathology|March 1, 1986
Haematological remission of leukaemic polymorphic immunocytoma following splenectomy. Case report with longitudinal immunological and cytogenetic studiesG Juliusson, A Ost, P Biberfeld, et al.
British Journal of Haematology|July 1, 1985
Prognostic value of B-cell mitogen-induced and spontaneous thymidine uptake in vitro in chronic B-lymphocytic leukaemia cellsG Juliusson, K H Robèrt, B Nilsson, et al.
European Journal of Cancer Care|July 10, 2015
Frequent and long-term follow-up of health-related quality of life following allogeneic haematopoietic stem cell transplantationU Frödin, K Lotfi, V Fomichov, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|March 10, 1994
[Progress in the treatment of hairy cell leukemia. Subcutaneous administration of 2-chloro-deoxy-adenosine for 7 days]D Heldal, G E Tjønnfjord, S A Evensen, et al.
British Journal of Haematology|March 1, 1995
Low-dose cladribine for symptomatic hairy cell leukaemiaG Juliusson, R Lenkei, G Tjønnfjord, et al.
Bone Marrow Transplantation|January 18, 2006
Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survivalG Juliusson, N Theorin, K Karlsson, et al.
Therapeutic Drug Monitoring|August 1, 1994
Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extractionF Albertioni, B Pettersson, V Reichelová, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL)F Albertioni, S Lindemalm, S Eriksson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosineV Reichelová, G Juliusson, T Spasokoukotskaja, et al.
Pageof 12